Segment Information

During the year ended December 31, 2014, the Company acquired Hi-Tech and as a result, underwent a change in the organizational and reporting structure of the Company’s reportable segments, establishing two reporting segments that each report to the Chief Operating Decision Maker (“CODM”), as defined in ASC Topic 280 - Segment Reporting, and CEO. Our performance is assessed and resources allocated by the CODM based on the following two reportable segments:


•	Prescription Pharmaceuticals


•	Consumer Health

The Company’s Prescription Pharmaceutical segment principally consists of generic and branded Prescription Pharmaceuticals products which span a broad range of indications as well as a variety of dosage forms including: sterile ophthalmics, injectables and inhalants, and non-sterile oral liquids, topicals and nasal sprays. The Company’s Consumer Health segment principally consists of animal health and OTC products, both branded and private label. OTC products include a suite of products for the treatment of dry eye sold under the TheraTears® brand name.

Financial information about each of the Company’s reportable segments is based upon internal financial reports that aggregate certain operating information. The Company’s CEO oversees operational assessments and resource allocations based upon the results of the Company’s reportable segments, which have available and discrete financial information.

Selected financial information by reporting segment is presented below (in thousands):



	Years ended December 31,
	2017		2016		2015
REVENUES, NET:
Prescription Pharmaceuticals	$	772,524	$	1,053,579	$	924,472
Consumer Health	68,521		63,264		60,604
Total revenues, net	$	841,045	$	1,116,843	$	985,076
GROSS PROFIT:
Prescription Pharmaceuticals	$	403,023	$	645,078	$	566,298
Consumer Health	30,124		29,193		29,714
Total gross profit	$	433,147	$	674,271	$	596,012

The Company manages its reportable business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level is minimal. The Company does not have discrete assets by segment, as certain manufacturing and warehouse facilities support more than one segment, and therefore does not report assets by segment. Financial information including revenues and gross profit from customers by product or product line is not provided, as to do so would be impracticable.

During the years ended December 31, 2017, 2016 and 2015, approximately $25.5 million, $26.3 million and $37.0 million of the Company’s net revenue, respectively, was from customers located in foreign countries. All of the net revenue is related to our Prescription Pharmaceutical segment.

The carrying amounts of Goodwill by segment were as follows (in thousands):



	Prescription Pharmaceuticals			Consumer Health		Total
December 31, 2015	$	267,993		$	16,717	$	284,710
Foreign currency translations	(417		)	—		(417		)
December 31, 2016	$	267,576		$	16,717	$	284,293
Foreign currency translations	1,017			—		1,017
December 31, 2017	$	268,593		$	16,717	$	285,310